Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01342224 · ClinicalTrials.gov registry record · Phase 1
Immunochemoradiotherapy in Patients With Pancreatic Cancer
A Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT01342224: Completed Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma, sponsored by Providence Health & Services.
NCT01342224 is a Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma that has completed, run by Providence Health & Services. The registered enrollment target is 11 participants, below the 66-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01342224, a Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will add an immunotherapy component to chemotherapy and radiation treatment in patients who have pancreatic cancer. The objective of this study is to see if the combined treatment is safe and feasible, and if a larger study is warranted.
Primary Outcome
Adverse events will be graded no less than weekly for the first 180 days. Post-treatment long-term follow-up will occur every 12 weeks beyond day 180 for 6 visits and then every 24 weeks thereafter until progressive disease, withdrawal from study or death. For this pilot study, adverse events and efficacy measures will be personally reviewed by the principal investigator. Both hematologic and non-hematologic toxicity will be anticipated. In conjunction with the IRB, stopping the trial will be am
Conditions Studied
Interventions
- BIOLOGICAL tadalafil and vaccination
Study Locations (1)
Oregon
- Providence Health & Services - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-01 |
| Est. Completion | 2018-04 |
| Phase | Phase 1 |
What the finished NCT01342224 record still lists
NCT01342224 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 66-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Locally Advanced Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which tadalafil and vaccination is the first listed.
NCT01342224 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT01342224 about?
NCT01342224 is a clinical study titled "Immunochemoradiotherapy in Patients With Pancreatic Cancer". This study will add an immunotherapy component to chemotherapy and radiation treatment in patients who have pancreatic cancer. The objective of this study is to see if the combined treatment is safe and feasible, and if a larger study is warranted.
What is the current status of trial NCT01342224?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2011-01. Estimated completion is 2018-04.
What conditions does trial NCT01342224 study?
This clinical trial studies the following conditions: Locally Advanced Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT01342224?
The interventions under investigation include: tadalafil and vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT01342224?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01342224 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01342224's enrollment target sits among peer trials
11 18th of 18 higher than 1 of 18 other Locally Advanced Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Locally Advanced Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
RECRUITING · Phase 1
-
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
RECRUITING · Phase 1
-
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 1
-
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
BATs Treatment for Pancreatic Cancer, Phase Ib/II
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia